Industry News
Virax sanguine on shortfall in $3.1m raising
Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has raised $3.1 million through a rights issue for the further development of its HIV therapeutic vaccine, falling $700,000 short of the $3.8 million the company planned to raise. [ + ]
LCT to raise additional US and European capital
Following the successful placement of more than AUD$3 million worth of shares in the US earlier this month, cell therapy company Living Cell Technologies (ASX:LCT) has revealed plans to raise at least a further AUD$8 million through a second tranche of shares in the US and Europe. [ + ]
Sydney team patents new ES cell growth method
A research team at Sydney's Prince of Wales Hospital has developed and patented a technique for growing human embryonic stem (ES) cells without using animal-derived feeder cells. [ + ]
Canberra summit to explore Australia's genetic research prospects
Federal and state MPs are to get an insight into Australian genetic and genomic research capabilities and opportunities, at a national forum to be held in Canberra in February. [ + ]
US vaccine firm plans ASX listing
US-based private vaccine development company Vaccinoma is planning to raise AUD$15 million through an IPO on the ASX in early April. [ + ]
Phylogica to collaborate with Canadian biotech
Perth-based Phylogica (ASX:PYC) has entered into an international collaboration agreement with Canadian biotechnology company Axela Biosensors to fast track the discovery new drug candidates for inflammatory disease. [ + ]
Burrill expects good year for biotech
The year 2006 will be a good one for biotech, according to San Francisco's bullish biotech maven, Steve Burrill. [ + ]
Govts should stay out of agbiotech business: Raff
Government involvement in agricultural biotech industries is stifling innovation, a leading industry figure has warned. [ + ]
Ellex sells property for $4.43m
Adelaide company Ellex Medical Lasers (ASX:ELX) has signed a contract for the sale of its building in Adelaide for a price of $4.43 million. [ + ]
Anadis hopes to extend Travelan uses
Melbourne biopharma Anadis (ASX:ANX) is investigating the use of its over-the-counter traveller's diarrhoea product, Travelan, for additional gastrointestinal therapeutic indications. [ + ]
Natural chemistry finds it way to market
Faster reaction rates, a substantially higher yield and a cleaner production process than is currently possible in the chemical industry, is claimed to be the result of a new sustainable chemical process that researchers from the Universiteit van Amsterdam and Radboud Universiteit Nijmegen have developed with support from NWO ACTS (Advanced Chemical Technologies for Sustainability).
[ + ]Infertility expert appointed Victorian governor
The Victorian premier, Steve Bracks, has appointed renowned Melbourne endocrinologist Prof David de Kretser, AO, to succeed John Landy as the state's governor. [ + ]
NeuroDiscovery and CSIRO sign collaboration agreement
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) and the CSIRO have entered into a research collaboration agreement. [ + ]
Clover cancels AIM listing
Sydney-based Clover (ASX:CLV) has applied to the London Stock Exchange to cancel its listing on the Alternative Investment Market (AIM). [ + ]
Drug giant Roche to offer clinical services
In what it believes is an industry first, Roche Pharmaceuticals will offer its clinical development services to outside customers, particularly non-government organisations (NGOs), according to the drug giant's global head of clinical pharmacology development, Prof Graham McClelland. [ + ]
